

Editorials

- Testing the Wrong Hypothesis in Phase II Oncology Trials: There Is a Better Alternative.**
□□ *Commentary on Vickers et al., p. 972*
Mark J. Ratain and Theodore G. Karrison.....781
- Phase 0 Trials: Are They Ethically Challenged?**
T. Patrick Hill.....783

The Biology Behind

- Anti-CTL-Associated Antigen 4: Are Regulatory T Cells a Target?**
□□ *Commentary on O'Mahony et al., p. 958*
Emmanuel M. Gabriel and Edmund C. Lattime.....785

Molecular Pathways

- Reactive Oxygen Species: A Breath of Life or Death?**
John P. Fruehauf and Frank L. Meyskens, Jr.....789
- Nitric Oxide and Its Gatekeeper Thrombospondin-1 in Tumor Angiogenesis.**
David D. Roberts, Jeffery S. Isenberg, Lisa A. Ridnour, and David A. Wink.....795

Human Cancer Biology

- Proteomic Signature Corresponding to the Response to Gefitinib (Iressa, ZD1839), an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma.** Tetsuya Okano, Tadashi Kondo, Kiyonaga Fujii, Toshihide Nishimura, Toshimi Takano, Yuichiro Ohe, Koji Tsuta, Yoshihiro Matsuno, Akihiko Gemma, Harumi Kato, Shoji Kudoh, and Setsuo Hirohashi.....799
- Gene Expression Signatures for Tumor Progression, Tumor Subtype, and Tumor Thickness in Laser-Microdissected Melanoma Tissues.** Jochen Jaeger, Dirk Koczan, Hans-Juergen Thiesen, Saleh M. Ibrahim, Gerd Gross, Rainer Spang, and Manfred Kunz.....806
- Myeloma Cell-Osteoclast Interaction Enhances Angiogenesis Together with Bone Resorption: A Role for Vascular Endothelial Cell Growth Factor and Osteopontin.** Yoichi Tanaka, Masahiro Abe, Masahiro Hiasa, Asuka Oda, Hiroe Amou, Ayako Nakano, Kyoko Takeuchi, Kenichi Kitazoe, Shinsuke Kido, Daisuke Inoue, Keiji Moriyama, Toshihiro Hashimoto, Shuji Ozaki, and Toshio Matsumoto.....816
- Expression of Voltage-Gated Potassium Channels in Human and Mouse Colonic Carcinoma.** Jiraporn Ousingsawat, Melanie Spitzner, Supaporn Puntheeranurak, Luigi Terracciano, Luigi Tornillo, Lukas Bubendorf, Karl Kunzelmann, and Rainer Schreiber.....824
- Epigenetic Inactivation of the Chromosomal Stability Control Genes *BRCA1*, *BRCA2*, and *XRCC5* in Non-Small Cell Lung Cancer.** Ming-Ni Lee, Ruo-Chia Tseng, Han-Shui Hsu, Jia-Yang Chen, Ching Tzao, William L. Ho, and Yi-Ching Wang.....832
- Germline Mutations in the *BRCA2* Gene and Susceptibility to Hereditary Prostate Cancer.** Ilir Agalliu, Erika M. Kwon, Daniel Zadory, Laura McIntosh, Joseph Thompson, Janet L. Stanford, and Elaine A. Ostrander.....839
- Somatic *TP53* Mutations Are Relatively Rare among Adrenocortical Cancers with the Frequent 17p13 Loss of Heterozygosity.** Rossella Libè, Lionel Groussin, Frédérique Tissier, Caroline Elie, Fernande René-Corail, Amato Fratticci, Eric Jullian, Paolo Beck-Peccoz, Xavier Bertagna, Christine Gicquel, and Jérôme Bertherat.....844
- Radiation-Induced Hepatitis B Virus Reactivation in Liver Mediated by the Bystander Effect from Irradiated Endothelial Cells.** Chia Hung Chou, Pei-Jer Chen, Po-Huang Lee, Ann-Lii Cheng, Hui-Chen Hsu, and Jason Chia-Hsien Cheng.....851

NF-Y–Dependent Cyclin B2 Expression in Colorectal Adenocarcinoma. Seon-Hwa Park, Gyung-Ran Yu, Woo-Ho Kim, Woo-Sung Moon, Jong-Hun Kim, and Dae-Ghon Kim	858
Implications of Endocrine Gland–Derived Vascular Endothelial Growth Factor/Prokineticin-1 Signaling in Human Neuroblastoma Progression. Elly S.W. Ngan, Francesco Y.L. Sit, King Liu Lee, Xiaoping Miao, Zhengwei Yuan, Weilin Wang, John M. Nicholls, Kenneth K.Y. Wong, Mercè Garcia-Barcelo, Vincent C.H. Lui, and Paul K.H. Tam	868

Imaging, Diagnosis, Prognosis

α1-Antitrypsin Precursor in Gastric Juice Is a Novel Biomarker for Gastric Cancer and Ulcer. Ping-I Hsu, Chung-Hsuan Chen, Chieu-Shia Hsieh, Wei-Chao Chang, Kwok-Hung Lai, Gin-Ho Lo, Ping-Ning Hsu, Feng-Woei Tsay, Yu-Shan Chen, Michael Hsiao, Hui-Chun Chen, and Pei-Jung Lu.....	876
WWOX Expression in Different Histologic Types and Subtypes of Non–Small Cell Lung Cancer. Valentina Donati, Gabriella Fontanini, Matteo Dell’Omodarme, Maria Cristina Prati, Simona Nuti, Marco Lucchi, Alfredo Mussi, Muller Fabbri, Fulvio Basolo, Carlo Maria Croce, and Rami Ishaq Aqeilan	884
Increased Expression of SIM2-s Protein Is a Novel Marker of Aggressive Prostate Cancer. Ole Johan Halvorsen, Kari Rostad, Anne Margrete Øyan, Hanne Puntervoll, Trond Hellem Bø, Laila Stordrange, Sue Olsen, Svein Andreas Haukaas, Leroy Hood, Inge Jonassen, Karl-Henning Kalland, and Lars Andreas Akslen	892
Vascular Endothelial Growth Factor Gene Polymorphisms Are Associated with Prognosis in Ovarian Cancer. Lukas A. Hefler, Alexander Mustea, Dominique Könsgen, Nicole Concin, Berno Tanner, Reiner Strick, Georg Heinze, Christoph Grimm, Eva Schuster, Clemens Tempfer, Alexander Reinthaller, and Robert Zeillinger	898
FOXP3⁺ Regulatory T Cells Affect the Development and Progression of Hepatocarcinogenesis. Noritoshi Kobayashi, Nobuyoshi Hiraoka, Wataru Yamagami, Hidenori Ojima, Yae Kanai, Tomoo Kosuge, Atsushi Nakajima, and Setsuo Hirohashi.....	902
Decreased Expression of Gene Cluster at Chromosome 1q21 Defines Molecular Subgroups of Chemoradiotherapy Response in Esophageal Cancers. Madan G. Luthra, Jaffer A. Ajani, Julie Izzo, Joe Ensor, Tsung-Teh Wu, Asif Rashid, Li Zhang, Alexandria Phan, Norio Fukami, and Rajyalakshmi Luthra	912
Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the Cell Search System. Sabine Riethdorf, Herbert Fritsche, Volkmar Müller, Thomas Rau, Christian Schindlbeck, Brigitte Rack, Wolfgang Janni, Cornelia Coith, Katrin Beck, Fritz Jänicke, Summer Jackson, Terrie Gornet, Massimo Cristofanilli, and Klaus Pantel	920
The ABCA5 Protein: A Urine Diagnostic Marker for Prostatic Intraepithelial Neoplasia. Youji Hu, Min Wang, Karen Veverka, Fernando U. Garcia, and Mark E. Stearns	929
The Time-Resolved Fluorescence-Based PCA3 Test on Urinary Sediments after Digital Rectal Examination; a Dutch Multicenter Validation of the Diagnostic Performance. Martijn P.M.Q. van Gils, Daphne Hessels, Onno van Hooij, Sander A. Jannink, W. Pim Peelen, Suzanne L.J. Hanssen, J. Alfred Witjes, Erik B. Cornel, Herbert F.M. Karthaus, Geert A.H.J. Smits, Gerhard A. Dijkman, Peter F.A. Mulders, and Jack A. Schalken	939
CpG Island Methylator Phenotype Association with Elevated Serum α-Fetoprotein Level in Hepatocellular Carcinoma. Changsong Zhang, Zhengyou Li, Yue Cheng, Fengqi Jia, Rong Li, Mengchao Wu, Ke Li, and Lixin Wei.....	944
Epidermal Growth Factor Receptor Protein Expression and Gene Amplification in Small Cell Carcinoma of the Urinary Bladder. Xiaoyan Wang, Shaobo Zhang, Gregory T. MacLennan, John N. Eble, Antonio Lopez-Beltran, Ximing J. Yang, Chong-Xian Pan, Honghong Zhou, Rodolfo Montironi, and Liang Cheng.....	953

Cancer Therapy: Clinical

- A Pilot Study of CTLA-4 Blockade after Cancer Vaccine Failure in Patients with Advanced Malignancy.** Deirdre O'Mahony, John C. Morris, Cate Quinn, Wendy Gao, Wyndham H. Wilson, Barry Gause, Stefania Pittaluga, Sattva Neelapu, Margaret Brown, Thomas A. Fleisher, James L. Gulley, Jeffrey Schlom, Robert Nussenblatt, Paul Albert, Thomas A. Davis, Israel Lowy, Mike Petrus, Thomas A. Waldmann, and John E. Janik.....958
- Celecoxib and Mucosal Protection: Translation from an Animal Model to a Phase I Clinical Trial of Celecoxib, Irinotecan, and 5-Fluorouracil.** Milind M. Javle, Shousong Cao, Farukh A. Durrani, Lakshmi Pendyala, David D. Lawrence, Patrick F. Smith, Patrick J. Creaven, Diane C. Noel, Renuka V. Iyer, and Youcef M. Rustum.....965
- Setting the Bar in Phase II Trials: The Use of Historical Data for Determining "Go/No Go" Decision for Definitive Phase III Testing.** Andrew J. Vickers, Vennus Ballen, and Howard I. Scher972
- An Optimized Clinical Regimen for the Oncolytic Virus PV701.** Sébastien J. Hotte, Robert M. Lorence, Hal W. Hirte, Susan R. Polawski, Michael K. Bamat, James D. O'Neil, M. Scot Roberts, William S. Groene, and Pierre P. Major977
- A Phase 1 Escalating Single-Dose and Weekly Fixed-Dose Study of Cetuximab: Pharmacokinetic and Pharmacodynamic Rationale for Dosing.** Paula M. Fracasso, Howard Burris III, Matthew A. Arquette, Ramaswamy Govindan, Feng Gao, Lisa P. Wright, Sherry A. Goodner, F. Anthony Greco, Suzanne F. Jones, Noel Willcut, Catherine Chodkiewicz, Amit Pathak, Gregory M. Springett, George R. Simon, Daniel M. Sullivan, Raphaël Marcelpoil, Shelley D. Mayfield, David Mauro, and Christopher R. Garrett.....986
- Class III β -Tubulin Expression and Benefit from Adjuvant Cisplatin/Vinorelbine Chemotherapy in Operable Non-Small Cell Lung Cancer: Analysis of NCIC JBR.10.** Pascal Sève, Raymond Lai, Keyue Ding, Timothy Winton, Charles Butts, John Mackey, Charles Dumontet, Laith Dabbagh, Sarit Aviel-Ronen, Lesley Seymour, Marlo Whitehead, Ming-Sound Tsao, Frances A. Shepherd, and Tony Reiman994
- Clinical Pharmacodynamic Effects of the Growth Hormone Receptor Antagonist Pegvisomant: Implications for Cancer Therapy.** Donghua Yin, Franzanne Vreeland, Larry J. Schaaf, Robert Millham, Barbara A. Duncan, and Amarnath Sharma1000

Cancer Therapy: Preclinical

- Cell Type-Specific, Topoisomerase II-Dependent Inhibition of Hypoxia-Inducible Factor-1 α Protein Accumulation by NSC 644221.** Mark Creighton-Gutteridge, John H. Cardellina II, Andrew G. Stephen, Annamaria Rapisarda, Badarch Uranchimeg, Karen Hite, William A. Denny, Robert H. Shoemaker, and Giovanni Melillo.....1010
- Protein Kinase CK2 α as an Unfavorable Prognostic Marker and Novel Therapeutic Target in Acute Myeloid Leukemia.** Jin Seok Kim, Ju In Eom, June-Won Cheong, Ae Jin Choi, Jin Koo Lee, Woo Ick Yang, and Yoo Hong Min.....1019
- Cyclophosphamide-Using Nonmyeloablative Allogeneic Cell Therapy against Renal Cancer with a Reduced Risk of Graft-versus-Host Disease.** Masatoshi Eto, Masahiko Harano, Katsunori Tatsugami, Mamoru Harada, Yoriyuki Kamiryo, Keijiro Kiyoshima, Masumitsu Hamaguchi, Masazumi Tsuneyoshi, Yasunobu Yoshikai, and Seiji Naito1029
- Celecoxib Prevents Neuroblastoma Tumor Development and Potentiates the Effect of Chemotherapeutic Drugs *In vitro* and *In vivo*.** Frida Ponthan, Malin Wickström, Helena Gleissman, Ole M. Fuskevåg, Lova Segerström, Baldur Sveinbjörnsson, Christopher P.F. Redfern, Staffan Eksborg, Per Kogner, and John I. Johnsen1036
- Suberoylanilide Hydroxamic Acid, a Histone Deacetylase Inhibitor: Effects on Gene Expression and Growth of Glioma Cells *In vitro* and *In vivo*.** Dong Yin, John M. Ong, Jinwei Hu, Julian C. Desmond, Norihiko Kawamata, Bindu M. Konda, Keith L. Black, and H. Phillip Koeffler.....1045
- CD8⁺ T cells Reactive to Survivin Antigen in Patients with Multiple Myeloma.** Matthias Grube, Stephanie Moritz, Ellen C. Obermann, Katayoun Rezvani, Andreas Mackensen, Reinhard Andreesen, and Ernst Holler1053

Flaxseed and Its Lignans Inhibit Estradiol-Induced Growth, Angiogenesis, and Secretion of Vascular Endothelial Growth Factor in Human Breast Cancer Xenografts *In vivo*.
Malin Bergman Jungeström, Lilian U. Thompson, and Charlotta Dabrosin **1061**

Letters to the Editor

HDAC Inhibitors and Cardiac Safety. Rhoda Molife, Peter Fong, Michelle Scurr, Ian Judson, Stan Kaye, and Johann de Bono **1068**

In Response: Manisha H. Shah, Miguel A. Villalona-Calero, Guido Marcucci, John C. Byrd, and Michael R. Grever **1068**

About the Cover

The *TP53* tumor suppressor gene is located at 17p13.1. 17p13 allelic losses are very frequent in adrenocortical cancer, and somatic mutations of *TP53* are observed in a third of these neoplasms. In malignant adrenocortical tumors, somatic *TP53* mutations are associated with p53 accumulation, as determined by immunohistochemistry. The larger figure shows a nuclear staining for p53 in an adrenocortical cancer with a *TP53* mutation. By contrast, the smaller figure shows that staining for p53 is not significant in a tumor without *TP53* mutation (<1% of cells). For further details, please see Libè *et al.* on page 844 of this issue.

